Dna Plasmid-Encoding Interleukin-12/Hpv Dna Plasmids Therapeutic Vaccine Medi0457
Cervical Carcinoma
Explore 61 assets in Cervical Carcinoma →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
vaccine
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03439085CT.gov DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cervical Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dna Plasmid-Encoding Interleukin-12/Hpv Dna Plasmids Therapeutic Vaccine Medi0457 (this asset) | M.D. Anderson Cancer Center | P2 | CCC · 53 |
| Carboplatin | Advenchen Laboratories, LLC | P3 | BB |
| Hepatitis B Virus Vaccine | Eunice Dube | P4 | BB |
| Gardasil 9 Vaccine | Eunice Dube | P4 | BB |
| Nogitecan | Advenchen Laboratories, LLC | P3 | BB |
| Pembrolizumab | Mayo Clinic | P2 | BB |
| Adriamycin | Advenchen Laboratories, LLC | P3 | B |
| Trastuzumab | National Cancer Institute (NCI) | P2 | B |
| Durvalumab | M.D. Anderson Cancer Center | P2 | B |
+42 more in the Cervical Carcinoma cohort
Other indications for Dna Plasmid-Encoding Interleukin-12/Hpv Dna Plasmids Therapeutic Vaccine Medi0457
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Malignant Neoplasm | — | P2 | CCC · 53 |
| Anal Canal Carcinoma | — | P2 | CCC · 53 |
| Human Papilloma Virus Infection | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dna Plasmid-Encoding Interleukin-12/Hpv Dna Plasmids Therapeutic Vaccine Medi0457 in Cervical Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dna-plasmid-encoding-interleukin-12hpv-dna-plasmids-therapeutic-vaccine-medi0457-cervical-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →